Biotechnology
Price
$79.76
+10.01%Market Cap
$31.65B
Day High
$81.40
Day Low
$73.68
Moderna reported Q1 FY2026 revenue of $389M (+260.2% YoY) driven by product sales recovery, but posted a net loss of -$1.34B as cost of revenue surged 961% and operating losses widened, reflecting ongoing commercial-stage cost pressures and heavy pipeline investment.
Key risk: Negative Gross Margin and Cost Structure Imbalance
Cost of revenue at $955M vastly exceeded revenue of $389M in Q1 FY2026, producing a deeply negative gross margin. This likely reflects fixed manufacturing costs, inventory write-downs, or product mix issues that could persist if vaccine demand remains volatile or new products ramp slowly.
Other Biotechnology companies